FDA approves Tremfya for active Crohn's disease in adults
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
The Cardiology Advisor12h
Baqsimi Approved for Severe Hypoglycemia Treatment in Younger Patients
The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.
Clinical Advisor12h
FDA Approves Tremfya for Active Crohn Disease in Adults
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease.